Cytokine induction owing to LVAD support in canine models

Yamagishi, Takahiro; Oshima, Kiyohiro; Mohara, Jun; Hasegawa, Yoshihisa; Kanda, Tsugiyasu; Ishikawa, Seiichi; Morishita, Yasuo

doi:10.1016/s0041-1345(99)00240-7

Cited by 4 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are no published studies of the inflammatory markers described above during in vitro VAD testing although, such approaches are being incorporated into preclinical studies in animals. In a study that involved implanting nine dogs with and six dogs without VADs, TNFα levels in blood and renal tissues did not differ after 6 h ( 77 ). Changes in leukocyte counts and activation profiles have been explored in animal preclinical studies.…”

Section: Inflammation In Response To Ventricular Assist Devicesmentioning

confidence: 99%

The Inflammatory Response to Ventricular Assist Devices

et al. 2018

View full text Add to dashboard Cite

The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients who are ineligible for transplant has increased steadily in the last decade. In parallel, improvements in VAD design have reduced device size, cost, and device-related complications. These complications include infection and thrombosis which share underpinning contribution from the inflammatory response and remain common risks from VAD implantation. An added and underappreciated difficulty in designing a VAD that supports heart function and aids the repair of damaged myocardium is that different types of HF are accompanied by different inflammatory profiles that can affect the response to the implanted device. Circulating inflammatory markers and changes in leukocyte phenotypes receive much attention as biomarkers for mortality and disease progression. However, they are seldom used to monitor progress during and outcomes from VAD therapy or during the design phase for new devices. Even the partial reversal of heart damage associated with heart failure is a desirable outcome from VAD use. Therefore, improved understanding of the interplay between VADs and the recipient's inflammatory response would potentially increase their uptake, improve patient lives, and fuel research related to other blood-contacting medical devices. Here we provide a review of what is currently known about inflammation in heart failure and how this inflammatory profile is altered in heart failure patients receiving VAD therapy.

show abstract

Section: Inflammation In Response To Ventricular Assist Devicesmentioning

confidence: 99%

The Inflammatory Response to Ventricular Assist Devices

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The present study is subject to a series of limitations. First, the LVAD is designed to be used in patients with heart failure; therefore, our results may not be directly applicable in clinical practice, because we used a healthy heart, as described elsewhere [ 53 , 54 ]. This limitation should be addressed in an animal cardiogenic shock model.…”

Section: Discussionmentioning

confidence: 99%

Effects of Sevoflurane and Propofol on Organ Blood Flow in Left Ventricular Assist Devices in Pigs

Morillas-Sendín

Delgado-Baeza

Delgado-Martos

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

The aim of this study was to assess the effect of sevoflurane and propofol on organ blood flow in a porcine model with a left ventricular assist device (LVAD). Ten healthy minipigs were divided into 2 groups (5 per group) according to the anesthetic received (sevoflurane or propofol). A Biomedicus centrifugal pump was implanted. Organ blood flow (measured using colored microspheres), markers of tissue injury, and hemodynamic parameters were assessed at baseline (pump off) and after 30 minutes of partial support. Blood flow was significantly higher in the brain (both frontal lobes), heart (both ventricles), and liver after 30 minutes in the sevoflurane group, although no significant differences were recorded for the lung, kidney, or ileum. Serum levels of alanine aminotransferase and total bilirubin were significantly higher after 30 minutes in the propofol group, although no significant differences were detected between the groups for other parameters of liver function, kidney function, or lactic acid levels. The hemodynamic parameters were similar in both groups. We demonstrated that, compared with propofol, sevoflurane increases blood flow in the brain, liver, and heart after implantation of an LVAD under conditions of partial support.

show abstract

“…This could limit the induction of an animal model of ischemic heart failure with uniform dysfunction. In this study, a healthy heart was used, as described elsewhere ( Jassawalla et al, 1988 ; Yamagishi et al, 2001 ; Kihara et al, 2003 ; Farrar et al, 2007 ; Slaughter et al, 2011 ; Tuzun et al, 2011 ; Morillas-Sendín et al, 2015 ), therefore further investigations are necessary to reproduce these results in patients with cardiogenic shock. Second, in thermodilution CO measurements, it is important to note the respiratory cycle, because the CO determined without regard to the respiratory cycle varies 1.4–1.7 L/min.…”

Section: Limitations and Future Directionsmentioning

confidence: 99%

New Advances in Monitoring Cardiac Output in Circulatory Mechanical Assistance Devices. A Validation Study in a Porcine Model

et al. 2021

View full text Add to dashboard Cite

Cardiac output (CO) measurement by continuous pulmonary artery thermodilution (COCTD) has been studied in patients with pulsatile-flow LVADs (left ventricular assist devices), confirming the clinical utility. However, it has not been validated in patients with continuous-flow LVADs. Therefore, the aim of this study was to assess the validity of COCTD in continuous-flow LVADs. Continuous-flow LVADs were implanted in six miniature pigs for partial assistance of the left ventricle. Both methods of measuring CO—measurement by COCTD and intermittent pulmonary artery thermodilution, standard technique (COITD)—were used in four consecutive moments of the study: before starting the LVAD (basal moment), and with the LVAD started in normovolemia, hypervolemia (fluid overloading), and hypovolemia (shock hemorrhage). At the basal moment, COCTD and COITD were closely correlated (r2 = 0.97), with a mean bias of −0.13 ± 0.16 L/min and percentage error of 11%. After 15 min of partial support LVAD, COCTD and COITD were closely correlated (r2 = 0.91), with a mean bias of 0.31 ± 0.35 L/min and percentage error of 20%. After inducing hypervolemia, COCTD and COITD were closely correlated (r2 = 0.99), with a mean bias of 0.04 ± 0.07 L/min and percentage error of 5%. After inducing hypovolemia, COCTD and COITD were closely correlated (r2 = 0.74), with a mean bias of 0.08 ± 0.22 L/min and percentage error of 19%. This study shows that continuous pulmonary thermodilution could be an alternative method of monitoring CO in a porcine model with a continuous-flow LVAD.

show abstract

Cytokine induction owing to LVAD support in canine models

Cited by 4 publications

References 8 publications

The Inflammatory Response to Ventricular Assist Devices

The Inflammatory Response to Ventricular Assist Devices

Effects of Sevoflurane and Propofol on Organ Blood Flow in Left Ventricular Assist Devices in Pigs

New Advances in Monitoring Cardiac Output in Circulatory Mechanical Assistance Devices. A Validation Study in a Porcine Model

Contact Info

Product

Resources

About